Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jack Adcock

Gynecology Joplin, MO Doctor of Osteopathy

NPI 1669487054 CMS profile 894248

3401 McIntosh Cir Ste 200, Joplin, MO 64804

Open in the dashboard

General payments

$18,336

162 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jack Adcock of Joplin, MO is reported in the CMS Open Payments database as having received $18,336 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,836 9
2023 General $620 6
2022 General $13,615 28
2021 General $1,206 55
2020 General $393 26
2019 General $665 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Adcock
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Jack Adcock were reported at $0. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Jack Adcock Gynecology median Middle half National median
2019 $665 $199 $66–$472 $163
2020 $393 $114 $42–$287 $114
2021 $1,206 $141 $42–$430 $132
2022 $13,615 $173 $52–$532 $149
2023 $620 $170 $57–$501 $160
2024 $1,836 $157 $50–$424 $164
2025 $0 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Intuitive Surgical, Inc. $13,905 15 payments
  2. Axonics Modulation Technologies, Inc. $2,026 17 payments
  3. AbbVie, Inc. $509 30 payments
  4. Astellas Pharma US Inc $439 20 payments
  5. Urovant Sciences Inc $193 7 payments
  6. Amgen Inc. $182 11 payments
  7. TherapeuticsMD, Inc. $171 11 payments
  8. Allergan Inc. $164 9 payments
  9. Caldera Medical, Inc $153 6 payments
  10. Coloplast Corp $78 5 payments
  11. Other $517 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $11,674 7 payments
  2. Travel and Lodging $3,432 12 payments
  3. Food and Beverage $2,645 139 payments
  4. Gift $585 4 payments
Products named General payments · program years 2019–2024
  1. DAVINCI XI $11,500 5 payments
  2. Da Vinci Surgical System $2,405 10 payments
  3. Axonics $1,856 10 payments
  4. Bulkamid $1,619 7 payments
  5. MYRBETRIQ $265 18 payments
  6. LO LOESTRIN FE $255 14 payments
  7. GEMTESA $193 7 payments
  8. Prolia $182 11 payments
  9. ORILISSA $177 11 payments
  10. ORIAHNN $164 9 payments
  11. Other $1,830 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

976

Median for Obstetrics & Gynecology: 65

Drug cost

$163,977

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

58.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 211 $90,925
Gemtesa Vibegron Brand 85 $54,589
Tolterodine Tartrate Er Tolterodine Tartrate Brand 97 $4,818
Estradiol Generic 146 $3,159
Trospium Chloride Generic 72 $2,476
Clobetasol Propionate Generic 22 $1,874
Methenamine Hippurate Generic 58 $1,278
Clindamycin Phosphate Generic 21 $1,260
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 75 $1,237
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 19 $683

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$29,973

Medicare's payments for the services billed

Medicare patients

154

Average age 75

Services billed

317

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 30%
Chronic kidney disease 27%
Ischemic heart disease 25%
Depression 25%
Osteoporosis 24%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record